

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**




FIG. 1C




FIG. 1B




FIG. 1A

6/7/85




FIG-2A




FIG-2B




FIG. 3




FIG. 4C




FIG. 4B





FIG. 4A


CD8 + T cells are the effector cells



F16.5

Fig-6

Effector to target ratio






FIG. 7

EFFECT OF PLURONIC/TWEEN ON CTL PRIMING




Fig. 8

EFFECT OF SQUALANE/TWEEN ON CTL PRIMING




FIG. 9

### EFFECT OF SQUALANE /PLURONIC ON CTL PRIMING




Fig:10

COMPARISON OF 30  $\mu$ g OVA IN CUSTOM  
3 OR 2 COMPONENT ADJUVANTS (Fig. 11)




Fig. 11

### Induction of anti-gp120IIIb antibodies in monkeys




Fig 12

**Antitumor activity of HOPE2 Cells after a Single Immunization  
(Day 10) of Soluble E7 Protein in Adjuvant**




Fig. 13

Antitumor Activity of HOPE2 Cells after a Two Immunizations  
(Day 10, 19) of Soluble E7 Protein in Adjuvant




Figure 14